References

1. Strachan DP. Epidemiology of hayfever: towards a community diagnosis. Clin Exp Allergy 1995; 25 (4):296-303.

2. Broder I, Higgins MW, Mathews KP, et al. Epidemiology of asthma and allergic rhinitis in a total community, Tecumsah, Michigan. 3. Second survey of the community. J Allergy Clin Immunol 1974; 53(3):127—138.

3. Schwindt CD, Hutcheson PS, Leu SY, et al. Role of intradermal skin tests in the evaluation of clinically relevant respiratory allergy assessed using patient history and nasal challenges. Ann Allergy Asthma Immunol 2005; 94(6):627-633.

4. Howarth PH. Allergic and nonallergic rhinitis. In: Adkinson NF, Yuninger JF, Busse WW, et al., eds. Allergy; Principles and Practice. 6th ed. Philadelphia, PA: Mosby, Inc., 2003:1391-1410.

5. Rajakulasingam K, Anderson DF, Holgate ST. Allergic rhinitis, nonallergic rhinitis, and ocular allergy. In: Kaplan AP, ed. Allergy. 2nd ed. Philadelphia, PA: WB Saunders Co., 1997:421-447.

6. Craig TJ, Teets S, Lehman EB. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998; 101(5):633-637.

7. Simons FER. Antihistimines. In: Adkinson NF, Yuninger JF, Busse WW, et al., eds. Allergy; Principles and Practice. 6th ed. Philadelphia, PA: Mosby, Inc., 2003:834-869.

8. Nelson HS. Mechanisms of intranasal steroids in the management of upper respiratory allergic diseases. J Allergy Clin Immunol 1999; 104(4 Pt 1):S138-S143.

9. Philip G, Malmstrom K, Hampel FC, et al. Montelukast for treating seasonal allergic rhinitis: doubleblind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32(7):1020-1028.

10. Durham SR, Walker SM, Varga EM, et al. Long term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341(7):468-475.

11. Greaves M, Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol 1991; 25 (1 Pt 2):155-161; discussion 161-165.

12. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165(14):1637-1642.

13. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol 2005; 53(3):373-388.

14. Kaplan A. Urticaria and angioedema. In: Adkinson NF, Yuninger JW, Busse WW, et al., eds. Allergy; Principles and Practice. 6th ed. Philadelphia, PA: Mosby, Inc., 2003:1537-1558.

15. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139(3):379-394; erratum in 2005; 141(1):189-190.

16. Sabroe RA, Black AK. Angiotensin converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 1997; 136(2):153-158.

17. Pigman EC, Scott JL. Angioedema in the emergency department: the impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med 1993; 11(4):350-354.

18. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75(4):349-354.

19. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161(5):714—718.

20. Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor—associated angioedema. JAMA 1997; 278(3):232-233.

21. Simon RA, Namazy J. Adverse reactions to aspirin and nonsteroidal antiinflammatory drugs (NSAIDs). Clin Rev Allergy Immunol 2003; 24(3):239-252.

22. Stevenson DD, Zuraw BL. Pathogenesis of aspirin-exacerbated respiratory disease. Clin Rev Allergy Immunol 2003; 24(2):169-188.

23. Nizankowska E, Bestynska-Krypel A, Cmiel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15(5):863-869.

24. McFadden EA, Woodson BT, Fink JN, et al. Surgical treatment of aspirin triad sinusitis. Am J Rhinol 1997; 11(4):263-270.

25. Dahlen B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 2000; 161(2 Pt 2):S137-S141.

26. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111 (1):180-186.

27. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922; 24:526-533.

28. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129(1): 92-96.

29. Wolf R, Orion E, Marcos B, et al. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005; 23(2):171-181.

30. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes oferythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138(8):1019-1024.

31. Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 1991; 127(5):740-741; comment 714-717.

32. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993; 129(4):466-468; comment Arch Dermatol 1994; 130(1):116-117.

33. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109(1):155-161.

34. Soter NA. Erythema Multiforme and Stevens-Johnson syndrome. In: Kaplan AP, ed. Allergy. 2nd ed. Philadelphia, PA: W. B. Saunders, Inc., 1997:643-651.

35. Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136(3):323-327; comment 410-411.

36. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139(1):33-36.

How To Deal With Rosacea and Eczema

How To Deal With Rosacea and Eczema

Rosacea and Eczema are two skin conditions that are fairly commonly found throughout the world. Each of them is characterized by different features, and can be both discomfiting as well as result in undesirable appearance features. In a nutshell, theyre problems that many would want to deal with.

Get My Free Ebook


Post a comment